Plecanatide Featured in New Publication on Constipation with Bloating
A new publication titled "Constipation with bloating: a clinical approach to evaluation and management" appeared in Annals of Medicine, dated Dec 1, 2026.
Read Full ArticleAll News
Buserelin Featured in New OHSS Trigger Comparison Study
A new publication examines buserelin among GnRH agonist triggers and OHSS rates in freeze-all cycles for high-risk patients, per Human Fertility journal.
VIP Research Cited in New Publication on Goat Colostrum and Constipation
A new publication in Food Research International references vasoactive intestinal peptide in a study on goat colostrum and gastrointestinal regulators, dated Dec 1, 2026.
New Protirelin Study Published in Neuropharmacology
A new publication on protirelin appeared in Neuropharmacology on Nov 15, 2026, examining TRH and dopaminergic interactions in rats.
GHK-Cu Study Published in Biomaterials Advances
A new publication on GHK-Cu appeared in Biomaterials Advances on 2026-11-01, examining poly(γ-benzyl-L-glutamate) microsphere structures and osteogenic-angiogenic coupling responses.
Retraction Notice Published for MicroRNA-27a Breast Cancer Study
A retraction notice for a study titled "MicroRNA-27a promotes tumorigenesis via targeting AKT in triple negative breast cancer" appeared in Molecular Medicine Reports on Nov 1, 2026.
FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know
Overview of the Regulatory Action According to a client alert from the law firm Buchanan Ingersoll & Rooney PC, the U.S.
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
Pharmacists Must Guide Peptide Talks Pending FDA Action, NCPA 2026 Session Signals Pharmacists are being urged to take a proactive role in counseling patients on peptide therapies even as the Food and Drug Administration continues to weigh how it will regulate this fast-growing category of compound...
Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients
Houston Compounding Pharmacy Faces Scrutiny After FDA Finds 14 Violations Tied to Recalled Tirzepatide Vials A Houston-based compounding pharmacy linked to a recall of compounded tirzepatide injectable vials was cited by the U.S.
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Vials Over Sterility Concerns Apothecary Pharma has issued a recall of compounded tirzepatide and NAD+ (nicotinamide adenine dinucleotide) injectable vials due to sterility concerns, according to a report from Managed Healthcare Executive.
North Carolina Compounder Recalls Tirzepatide Vials…
North Carolina Compounder Recalls Tirzepatide Vials Amid Ongoing Scrutiny of Compounded GLP-1 Products A compounding pharmacy based in North Carolina has issued a recall of tirzepatide vials, according to a report circulated via Google News and aggregated by inkl.
Twenty AGs Issue Letter on Chinese-Sourced Ingredients in Some Compounded GLP-1s and Peptides
Twenty State Attorneys General Raise Alarms Over Chinese-Sourced Ingredients in Compounded GLP-1 Drugs A coalition of twenty state attorneys general has issued a letter addressing concerns about Chinese-sourced active pharmaceutical ingredients (APIs) used in some compounded versions of GLP-1 recep...
Phase 4 Trial of Angiotensin II (Giapreza) in Pediatric Hypotension Updated
A Phase 4 trial studying synthetic angiotensin II (Giapreza) in pediatric patients with refractory hypotension is now enrolling by invitation as of Oct 23, 2026.
Phase 3 Trial Listed for Eptinezumab in Post-Traumatic Headache
A Phase 3 trial, ELITE-ACT, testing early eptinezumab infusion for acute post-traumatic headache was registered on 2026-10-23, status not yet recruiting.
Corticorelin-Related Study Published in Science Advances
A new publication titled "Neural circuitry mediating hypercapnia-induced microarousal and impaired sleep depth" appeared in Science Advances on Oct 23, 2026.
New Publication Reviews Skeletal Effects of GLP-1 Drugs Including Exenatide
A systematic review on skeletal effects of GLP-1 receptor agonist therapy, including exenatide, in adults with overweight or obesity was published Oct 23, 2026.
Glucagon-Linked Trial on Diet, Training and Fat-Mass Loss Updated
Trial NCT07113561 on high-protein diet and resistance training for fat-mass loss maintenance, involving glucagon, is now active but not recruiting as of Oct 23, 2026.
Gonadorelin Trial S1207 Status Updated: Active, Not Recruiting
Phase 3 trial S1207, testing hormone therapy with or without everolimus in breast cancer patients, is now active but not recruiting as of Oct 23, 2026.
Goserelin-Linked NATALEE Trial Six-Year Survival Data Published
New publication dated Oct 23, 2026 in Annals of Oncology reports six-year follow-up data from the NATALEE trial involving goserelin-associated regimens.
New Publication on Humanin Variants and BID/BAX Pathway Published
A new study on humanin variants and their effects on BID fibrilization and membrane permeabilization was published in The Journal of Biological Chemistry on Oct 23, 2026.
Insulin Glargine Trial NCT06627478 Completes Phase 1
Phase 1 trial comparing NKF-INS glargine with US-Lantus and EU-Lantus has completed, per a ClinicalTrials.gov update dated October 23, 2026.